Loading
A phase 3 trial of Omidubicel in Acute lymphoblastic leukaemia and Leukaemia, run by Gamida Cell ltd, completed.
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS is a phase 3 interventional study registered as NCT02730299 by Gamida Cell ltd, with 125 participants recorded, started 2016-12-16 and reaching its primary completion in 2021-04-29. Interventions recorded: NiCord® (omidubicel), Cord Blood Unit. Conditions recorded: Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Lymphoma, Acute Leukemia.
Linked to the drug Omidubicel because the registry names it among its interventions and Acute lymphoblastic leukaemia and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
125 enrolled.
95% CI 10 to 14; Figures from the ClinicalTrials.gov results section (first posted 2022-10-25), not from a publication · 95% CI 19 to 25
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Time to Neutrophil Engraftmentprimary | NiCord® (Omidubicel) | 62 | 12 days | - | - | link |
| Unmanipulated Cord Blood Unit(s) | 63 | 22 days |
Shares Leukaemia (all types), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.